# Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

> **NCT03878719** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 1 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** binimetinib
- **DRUG:** encorafenib

## Key facts

- **NCT ID:** NCT03878719
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-03
- **Primary completion:** 2022-08-19
- **Final completion:** 2022-08-19
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The trial was terminated early on 05 October 2022 due to non-feasibility and poor recruitment and not based on safety concerns.
- **Last updated:** 2023-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03878719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03878719, "Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03878719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*